Erenumab and galcanezumab in chronic migraine prevention: effects after treatment termination

BACKGROUND: Monoclonal antibodies (mAbs) targeting the CGRP pathway are safe and efficacious therapies for the prevention of migraine. In this study we assessed the effects of discontinuation of preventive erenumab and galcanezumab treatment in patients with chronic migraine. METHODS: This retrospec...

Descripción completa

Detalles Bibliográficos
Autores principales: Raffaelli, Bianca, Mussetto, Valeria, Israel, Heike, Neeb, Lars, Reuter, Uwe
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Milan 2019
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6734267/
https://www.ncbi.nlm.nih.gov/pubmed/31159727
http://dx.doi.org/10.1186/s10194-019-1018-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6734267/
https://www.ncbi.nlm.nih.gov/pubmed/31159727
http://dx.doi.org/10.1186/s10194-019-1018-8

Ejemplares similares